炒股就看金麒麟分析师研报，泰斗，专科，实时，全面，助您挖掘后劲主题契机！
Swipe Left For English News
1
慑服PSCI原则，共促价值链的可合手续和负包袱发展
2
凭借构建可合手续供应链的超卓计议力赢得奖项认同
3
引颈绿色生物药发展，时间编削赋能健康往日
上海,
2025年1月15日
大家首先的合同征询、斥地和坐褥（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）晓示，公司已闲隙加入“制药供应链倡议组织（PSCI）”，成为其供应商相助伙伴。这一举措体现了公司对诚信运营、超卓质地和可靠性的刚毅快活，并彰显了其戮力于推动构建负包袱供应链本质的决心。
PSCI 是大家制药和医疗健康范围的首先协会，其中枢管事是联袂相助伙伴推动负包袱价值链构建，已矣安全、环境和社会效益方面的超卓发扬。药明生物在说念德、劳工与东说念主权、健康与安全、环境和料理体系等维度剿袭PSCI所倡导的负包袱供应链原则，更将PSCI原则深度融入供应链料理体系，积极联袂大家供应链伙伴股东并实执行业最好本质，旨在为行业带来平凡而深入的积极影响。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
包容、负包袱且极具韧性的供应链是咱们业务制胜往日的关节。咱们很怡悦成为PSCI的一员，共同倡导在价值链上推论并践行负包袱的交易当作。揣测往日，咱们将合手续追求凸起的环境、社会和治理（ESG）发扬，并赋能大家相助伙伴，推动其迈向ESG发展新高度。
]article_adlist-->
近期，药明生物在2024年香港ESG报告大奖中荣获“可合手续供应链计议力奖”。公司戮力于和相似信守高说念德圭表的相助伙伴共同优化交易本质，运行行业发展。为践行这一快活，公司制定了可合手续供应链政策，设定了明确忖度打算，并辩论详备阶梯，依期开展慑服PSCI原则的审计，为供应链伙伴提供专科培训课程，同期积极探索才调竖立姿色。这些前瞻性举措将引颈公司稳步构建愈加透明、高说念德圭表且负包袱的供应链体系。
2024年，药明生物凭借首先的绿色生物药科罚决策（Green CRDMO），得胜入选长入国大家公约组织（UNGC）“‘二十年二十佳’企业可合手续发展案例”报告。此外，公司考虑两年赢得明晟（MSCI）最高AAA ESG评级；考虑两年入选说念琼斯可合手续发展指数（DJSI）；赢得海外泰斗企业可合手续发展评估机构EcoVadis“铂金”奖牌；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；踏进CDP水安全“A级榜单”并赢得CDP表象变化计议力级别评分A-；入选富时社会包袱指数系列；入选恒生ESG 50指数，充分彰显了公司在可合手续发展范围的超卓发扬。
]article_adlist-->
]article_adlist-->
对于药明生物
药明生物（股票代码：2269.HK）是一家大家首先的合同征询、斥地和坐褥（CRDMO）公司。公司通过绽放式、一体化生物制药才调和时间赋能平台，提供全主义的端到端服务，匡助相助伙伴发现、斥地及坐褥生物药，已矣从宗旨到交易化坐褥的全经过，加快大家生物药研发进度，裁汰研发资本，造福病患。
药明生物在中国、好意思国、爱尔兰、德国和新加坡领有超过12000名职工。通过药明生物的专科服务团队，以及先进时间和大约洞见，公司为客户提供高效经济的生物药科罚决策。为止2024年6月底，药明生物匡助客户研发和坐褥的概括姿色高达742个，其中包括16个交易化坐褥姿色（不包括新冠姿色和非活跃姿色）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的攻击组成部分，并戮力于成为大家生物药CRDMO范围的ESG计议者，举例行使更绿色环保的新一代生物制药时间和动力等引颈行业发展。公司设置了由首席执行官计议的ESG委员会，全面落实ESG计谋并践行可合手续性发展快活。更多信息，请看望：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体相关
PR@wuxibiologics.com
WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership
1
Committed to PSCI principles to promote a responsible supply chain
2
Recognized for sustainable supply chain leadership
3
As a leading Green CRDMO, driven by innovation for a healthier future
Shanghai,
January 15, 2025
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner, demonstrating its strong commitment to integrity, quality, reliability, and the advancement of responsible supply chain practices.
PSCI is the leading association for pharmaceutical and healthcare companies with a common vision of excellence in safety, environmental, and social outcomes across the global healthcare value chain. WuXi Biologics fully upholds PSCI principles for responsible supply chain practices in the areas of Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems. The company embeds PSCI principles into its own supply chain management system, actively engaging and collaborating with global suppliers to drive best practices and generate positive impacts.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
An inclusive, responsible, and resilient supply chain is key to our long-term business success, and we are pleased to join PSCI in advocating for responsible practices throughout the value chain. We will continuously deliver our own ESG excellence and enable our partners worldwide to fulfill their ESG commitments.
WuXi Biologics was recognized by the 2024 Hong Kong ESG Reporting Awards with a Sustainable Supply Chain Leadership Award for its outstanding performance. The company strives to conduct business with partners who share the same commitment to high ethical and sustainability standards. To create a more transparent, ethical, and responsible supply chain, WuXi Biologics formulates sustainable supply chain policies, sets tangible targets, develops refined roadmaps, performs regular PSCI audits, provides training courses, and explores capacity-building programs.
In 2024, WuXi Biologics was included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions. The company was granted an MSCI AAA Rating and included in Dow Jones Sustainability Indices for two consecutive years; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional ESG Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; selected as a Constituent of FTSE4Good Index Series; and listed in the Hang Seng ESG 50 Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
]article_adlist-->
注：本信息不组成药明生物的信息闪现或投资暴虐
海量资讯、精确解读，尽在新浪财经APP